L
Laura Kakkola
Researcher at University of Turku
Publications - 60
Citations - 2116
Laura Kakkola is an academic researcher from University of Turku. The author has contributed to research in topics: Virus & Medicine. The author has an hindex of 21, co-authored 49 publications receiving 1688 citations. Previous affiliations of Laura Kakkola include University of Helsinki & Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
Genetic Alterations in Hormone-Refractory Recurrent Prostate Carcinomas
TL;DR: Results suggest that recurrent prostate carcinomas are genetically unstable, and the resulting heterogeneity may well underlie the poor responsiveness of hormone-refractory tumors to treatment.
Journal ArticleDOI
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
Pinja Jalkanen,Pekka Kolehmainen,Hanni K. Häkkinen,Moona Huttunen,Paula A. Tähtinen,Rickard Lundberg,Sari Maljanen,Arttu Reinholm,Sisko Tauriainen,Sari H. Pakkanen,Iris Levonen,Arttu Nousiainen,Taru Miller,Hanna Välimaa,Lauri Ivaska,Arja Pasternack,Rauno Naves,Olli Ritvos,Pamela Österlund,Suvi Kuivanen,Teemu Smura,Jussi Hepojoki,Olli Vapalahti,Johanna Lempainen,Johanna Lempainen,Laura Kakkola,Anu Kantele,Ilkka Julkunen,Ilkka Julkunen +28 more
TL;DR: Jalkanen et al. as mentioned in this paper showed that after the second dose of BNT162b2-vaccinated health care workers (n = 180) effectively neutralized the SARS-CoV-2 variant with the D614G substitution and the B.1.7 variant, whereas the neutralization of B.351 variant is five-fold reduced.
Journal ArticleDOI
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
C. Palmberg,Pasi A. Koivisto,Laura Kakkola,Teuvo L.J. Tammela,Olli Kallioniemi,Tapio Visakorpi +5 more
TL;DR: Androgen receptor gene amplification detected in tumors progressing during androgen deprivation monotherapy is associated with favorable treatment response to second line combined androgen blockade, suggesting that at least some androgen receptor amplified tumors retain a high degree of dependency on residual androgens remaining in serum after monotherapy.
Journal ArticleDOI
Amplification and Overexpression of p40 Subunit of Eukaryotic Translation Initiation Factor 3 in Breast and Prostate Cancer
Nina N. Nupponen,Kati P. Porkka,Laura Kakkola,Minna Tanner,Karin Persson,Åke Borg,Jorma Isola,Tapio Visakorpi +7 more
TL;DR: High-level amplification of eIF3-p40 gene was found in 30% of hormone-refractory prostate tumors and in 18% of untreated primary breast tumors, implying that genomic aberrations of translation initiation factors, such as p40, may contribute to the pathogenesis of breast and prostate cancer.
Journal ArticleDOI
Obatoclax, saliphenylhalamide and gemcitabine inhibit influenza A virus infection
Oxana V. Denisova,Laura Kakkola,Lin Feng,Jakob Stenman,Ashwini S. Nagaraj,J Lampe,Bhagwan Yadav,Tero Aittokallio,Pasi Kaukinen,Tero Ahola,Suvi Kuivanen,Olli Vapalahti,Anu Kantele,Janne Tynell,Ilkka Julkunen,Hannimari Kallio-Kokko,Henrik Paavilainen,Veijo Hukkanen,Richard M. Elliott,Jef K. De Brabander,Xavier Saelens,Denis E. Kainov +21 more
TL;DR: The results suggest that phase II obatoclax, investigational SaliPhe, and FDA/EMEA-approved gemcitabine represent potent antiviral agents.